[go: up one dir, main page]

WO2018186705A1 - Composition contenant un extrait de résidus de siraitia grosvenorii à titre de principe actif, pour prévenir, soulager ou traiter l'inflammation - Google Patents

Composition contenant un extrait de résidus de siraitia grosvenorii à titre de principe actif, pour prévenir, soulager ou traiter l'inflammation Download PDF

Info

Publication number
WO2018186705A1
WO2018186705A1 PCT/KR2018/004042 KR2018004042W WO2018186705A1 WO 2018186705 A1 WO2018186705 A1 WO 2018186705A1 KR 2018004042 W KR2018004042 W KR 2018004042W WO 2018186705 A1 WO2018186705 A1 WO 2018186705A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
nahan
residue
composition
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/004042
Other languages
English (en)
Korean (ko)
Inventor
김동선
김온순
손은정
이윤미
이영실
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2018186705A1 publication Critical patent/WO2018186705A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones

Definitions

  • the present invention relates to a composition for the prevention, improvement or treatment of inflammation containing Nahan and residue extract as an active ingredient.
  • Inflammation refers to the pathological condition of an abscess formed by the invasion of external infectious agents (bacteria, fungi, viruses, various types of allergens). Specifically, when the external bacteria invade specific tissues and proliferate, the white blood cells of the living body recognize this, and actively attack the multiplying external bacteria. The dead sea of white blood cells generated during this process accumulates in the tissues invaded by the bacteria. At the same time, cell destruction of invading bacteria killed by leukocytes is fused into the invaded tissue, forming an abscess. Inflammation of the abscess may be promoted through anti-inflammatory action.
  • infectious agents bacteria, fungi, viruses, various types of allergens
  • Anti-inflammatory action is to use an antibacterial agent to inhibit the growth of invading bacteria or to activate macrophages that feed on the foreign substances accumulated in the abscess to digest the foreign substances. And promotes inflammation, such as promoting the function of the macrophages to excrete.
  • an inflammatory reaction is a biodefense reaction process for repairing and regenerating damage caused by an invasion that causes organic changes in cells or tissues of a living body, and this reaction process includes local blood vessels, various tissue cells of body fluids and immune cells, etc.
  • This works Normally, the inflammatory response induced by external invading bacteria is a defense system for protecting the living body, whereas abnormally excessive inflammatory response is induced, and various diseases appear. These diseases are called inflammatory diseases.
  • the inflammatory disease is a disease that threatens human life by amplifying and sustaining inflammation of various inflammatory mediators secreted from target cells activated by external stimuli.
  • Inflammatory diseases caused by such inflammation include asthma, chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular Degeneration, uveitis, conjunctivitis, arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammation Diseases, endometritis, rhinitis, tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis.
  • Sihantia grosvenori is a perennial herb that is grown in the highlands of Guangdong, Guangxi, China. Fruits are egg-shaped or spherical, 4 ⁇ 5cm in diameter. If there is a problem with the stomach or intestines, it was used in the private sector.
  • Korean Patent Publication No. 2015-0132654 discloses a pharmaceutical composition for the prevention or treatment of inflammatory diseases comprising extracts, fractions thereof or compounds isolated therefrom.
  • a pharmaceutical composition for the prevention, improvement or treatment of inflammation containing Nahan and residue extract of the present invention as an active ingredient.
  • the present invention is derived from the above requirements, the present invention provides a composition for the prevention, improvement or treatment of inflammation containing Nahan and residue extract as an active ingredient, the Nahan and residue extract according to the present invention is cytotoxic
  • the present invention has been shown to have the effect of inhibiting the production of NO induced by inflammation, an increase in PGE 2 and IL-1 ⁇ , and reducing the content of cytokines and chemokines in cells in which atopic dermatitis is induced. Completed.
  • the present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory diseases containing Nahan and residue extract as an active ingredient.
  • the present invention provides a health functional food composition for the prevention or improvement of inflammation comprising the extract of Nahan and the residue as an active ingredient.
  • the present invention provides a cosmetic composition for improving atopic dermatitis comprising Nahan and residue extract as an active ingredient.
  • the present invention relates to a composition for the prevention, improvement or treatment of inflammation containing Nahan and the residue extract as an active ingredient, Nahan and the residue extract of the present invention is the production of NO induced by inflammation, PGE 2 and IL It is excellent in inhibiting the increase of -1 ⁇ and significantly decreases the content of cytokines or chemokines in the cells in which atopic dermatitis or dermatitis is induced, and thus prevents, improves or treats inflammation in medicines, functional foods or cosmetics. It can be useful.
  • Figure 2 shows that the production of NO increased by the treatment of LPS (lipopolysaccharide) in RAW 264.7 cells, the result of confirming that the production of NO increased by LPS by treating the Nahan and the extract of Nahan and the residue of the present invention.
  • ### indicates that NO production increased significantly compared to the negative control group by treatment of LPS, p ⁇ 0.001, and *** means that NO production increased by LPS was lower than that of the present invention. It was statistically significantly reduced by the treatment of and residue extract, p ⁇ 0.001.
  • FIG. 3 shows the results of reducing the production of PGE 2 by treating the extract of Nahan and the extract of Nahan and the residue of the present invention with respect to PGE 2 production induced by lipopolysaccharide (LPS) in RAW 264.7 cells. ** and *** indicate that the PGE 2 production increased by LPS was statistically significantly reduced by the treatment of Nahan and the residue extract of the present invention, ** is p ⁇ 0.01, *** is p ⁇ 0.001 to be.
  • LPS lipopolysaccharide
  • Figure 5 is a result confirming the MC / 9 mast cell toxicity of Nahan and the residue extract.
  • TNF- ⁇ (A) and IL-6 (B) contents of the PMACI group were significantly increased compared to the normal group, p ⁇ 0.001, and *** is the lower limit of the present invention compared to the PMACI group.
  • the content of TNF- ⁇ (A) and IL-6 (B) of the group treated with the debris extract or the positive control dexamethasone was significantly decreased, which means p ⁇ 0.001.
  • Figure 7 is the result of confirming HaCaT cytotoxicity of Nahan and the residue extract.
  • TI is a group treated with TNF- ⁇ and IFN- ⁇ to induce dermatitis.
  • ### represents a statistically significant increase in the contents of RANTES (A), TARC (B) and IL-8 (C) in the TI group compared to the normal group, with p ⁇ 0.001, *, **, ** * Is the content of RANTES (A), TARC (B) and IL-8 (C) of the group treated with Nahan and the residue extract or positive control group (desamethason, cyclosporin A or silymarin) of the present invention compared to the TI group Significantly reduced, * means p ⁇ 0.05, ** means p ⁇ 0.01, and *** means p ⁇ 0.001.
  • the present invention relates to a pharmaceutical composition for the prophylaxis or treatment of inflammatory diseases containing Nahan and residue extract as an active ingredient.
  • the extraction solvent is preferably water, a lower alcohol of C 1 ⁇ C 4 or a mixture thereof, and more preferred extraction solvent is water, but is not limited thereto.
  • the inflammatory diseases include asthma, chronic obstructive pulmonary disease, allergies, systemic lupus erythematosus, scleroderma, ulcerative colitis, Crohn's disease, atopic dermatitis, psoriasis, anaphylaxis, dermatitis, diabetic retinopathy, retinitis, macular degeneration, uveitis, conjunctivitis, Arthritis, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, osteoporosis, diabetes, diabetic nephropathy, nephritis, nephritis, Sjogren's syndrome, Crohn's disease, autoimmune pancreatitis, periodontal disease, graft-versus-host disease, chronic pelvic inflammatory disease, endometritis, rhinitis , Tonsillitis, otitis media, sore throat, cystitis and chronic prostatitis is preferably
  • the pharmaceutical composition comprising the extract of Nahan and the residue according to the present invention is preferably a formulation of a cream, gel, patch, spray, ointment, warning, lotion, linen, pasta or cataplasma, but is not limited thereto. .
  • the Nahan and the residue extract may further comprise a pharmaceutically acceptable carrier, excipient or diluent, carriers, excipients or diluents that may be included in the pharmaceutical composition
  • a pharmaceutically acceptable carrier excipient or diluent, carriers, excipients or diluents that may be included in the pharmaceutical composition
  • the Nahan and residue extract lactose, dextrose, Sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxy Benzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • diluents or excipients such as fillers, extenders, binders,
  • the preferred dosage of the Nahan and residue extract of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art.
  • the pharmaceutical composition comprising the extract of Nahan and the residue of the present invention is preferably administered at 0.0001 to 100mg / kg, preferably 0.001 to 10mg / kg per day. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the present invention relates to a health functional food composition for the prevention or improvement of inflammation comprising the extract of Nahan and the residue as an active ingredient.
  • the dietary supplement composition of the present invention may be prepared in any one formulation selected from powders, granules, pills, tablets, capsules, candy, syrups and beverages, but is not limited thereto.
  • the health functional food composition of the present invention When used as a food additive, the health functional food composition may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method.
  • the active ingredient may be appropriately used depending on the purpose of use (prevention or improvement).
  • the nutraceutical composition of the present invention is added in an amount of 15 parts by weight or less, preferably 10 parts by weight or less with respect to the raw material.
  • the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.
  • dietary supplement there is no particular limitation on the type of dietary supplement.
  • foods to which the health functional food composition may be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products, including ice cream, various soups, drinks, tea Drinks, alcoholic beverages, vitamin complexes, and the like, and include all health foods in the conventional sense.
  • the nutraceutical composition of the present invention may be prepared as a food, in particular a functional food.
  • the functional food of the present invention may include ingredients that are commonly added. Examples include proteins, carbohydrates, fats, nutrients and seasonings.
  • natural carbohydrates or flavors may be included as additional ingredients in addition to the active ingredient.
  • the natural carbohydrates can be monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g. dextrins, cyclodextrins, etc.) or sugar alcohols (e.g.
  • the flavourant may be a natural flavourant (eg, taumartin, stevia extract, etc.) and a synthetic flavourant (eg, saccharin, aspartame, etc.).
  • the carbonation agent etc. which are used for a drink can be contained further.
  • the ratio of the above-mentioned ingredients is not critical, it is generally selected from 0.01 to 0.1 parts by weight based on 100 parts by weight of the health functional food composition of the present invention.
  • the present invention relates to a cosmetic composition for improving atopic dermatitis comprising the extract of Nahan and the residue as an active ingredient.
  • the cosmetic composition for improving atopic dermatitis is a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleansing, oil, powder It can be prepared in any of the formulations selected from foundation, foundation, wax foundation, and spray, and it can be used for skin ointments, creams, softeners, nourishing lotions, packs, essences, hair tonics, shampoos, rinses, hair conditioners, hair treatments, Gel, Skin Lotion, Skin Softener, Skin Toner, Astringent, Lotion, Milk Lotion, Moisture Lotion, Nutrition Lotion, Massage Cream, Nutrition Cream, Moisture Cream, Hand Cream, Foundation, Nutrition Essence, Sunscreen, Soap, Cleansing Foam, Cleansing It may have any one formulation selected from the group consisting of lotion, cleansing cream, body lotion and body cleanser, This is not restrictive.
  • the cosmetic composition consisting of each of these formulations may contain various bases and additives necessary for the formulation of the
  • the carrier component is animal fiber, vegetable fiber, wax, paraffin, starch, tragacanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide. And the like can be used.
  • the formulation of the cosmetic composition of the present invention is a powder or a spray
  • lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as the carrier component, and in particular, in the case of a spray, additionally chlorofluorohydro Propellants such as carbon, propane-butane or dimethyl ether.
  • a solvent, solvating agent or emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene.
  • a carrier component such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene.
  • the formulation of the cosmetic composition of the present invention is a suspension
  • a carrier component water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Microcrystalline cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
  • the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, acethionate, an imidazolinium derivative, a methyltaurate, or a sarcosinate.
  • Fatty acid amide ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
  • RAW 264.7 cells which are mouse macrophage lines, were dispensed in 96-well plates at appropriate concentrations, and then the Nahan and extracts prepared in Examples 1 and 2 were treated at different concentrations (100, 200 ⁇ g / ml). Incubated for 24 hours. After culturing the cells, the MTT solution was added and reacted for 4 hours, and then the absorbance of 540 nm was measured using an ELISA reader. The relative cell viability was calculated by comparison with the control group.
  • the Nahan and the residue extracts of the present invention reduced the NO production increased by LPS in a concentration-dependent manner, but the Nahan extract had no effect on the decrease of the NO production increased by LPS. I could't.
  • both the Nahan and the residue extract and Nahan and the extract of the present invention reduced the amount of PGE 2 produced by LPS, and the Nahan and the residue extract of the present invention were more effective than the Nahan and the extract. PGE 2 production was reduced.
  • LPS 400 ng / ml
  • the Nahan and extracts prepared in Examples 1 and 2 were separated by concentration (100, 200 ⁇ g / ml).
  • the amount of IL-1 ⁇ production was measured according to the manufacturer's method using the IL-1 ⁇ ELISA kit.
  • the Nahan fruit residue extract of the present invention significantly reduced the amount of IL-1 ⁇ produced by LPS as compared to Nahan fruit extract.
  • Mouse mast cell MC / 9 cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA) to obtain 10% heat-inactivated Fetal Bovine Serum (FBS), 100 units / ml penicillin and 100 Incubated in 37%, 5% CO 2 environment in DMEM medium with ⁇ g / ml of streptomycin (streptomycin). It was used to evaluate the cytotoxicity and inhibitory effect of cytokine secretion of Nahan and the residue extract.
  • FBS Fetal Bovine Serum
  • streptomycin streptomycin
  • a Cell Counting Kit-8 (CCK-8) assay was performed. Samples were treated in MC / 9 mast cells in 96-well plates by concentration (50, 100, 200 ⁇ g / ml) and incubated for 24 hours. After adding CCK-8 at 10% concentration and reacting at 37 ° C. for 2 hours, absorbance at 450 nm was measured using a microplate spectrophotometer (Biorad, Hercules, CA, USA). Relative cell viability was calculated by comparison of.
  • Cultured MC / 9 mouse mast cells were inoculated into 96-well plates, and then treated with atopy-inducing substance, 20 nM of PMA (phorbol myristate acetate) and calcium ionophore (CI) of A23187 at a concentration of 0.5 ⁇ M.
  • atopy-inducing substance 20 nM of PMA (phorbol myristate acetate) and calcium ionophore (CI) of A23187 at a concentration of 0.5 ⁇ M.
  • co-cultivation was carried out with various concentrations (50, 100, 200 ⁇ g / ml) of Hanhan and residue extracts.
  • 0.1 ⁇ M and 1 ⁇ M of dexamethasone were treated, respectively.
  • cytokines TNF- ⁇ and IL-6
  • ELISA kit R & D systems Inc., Minneapolis, MN, USA. 100% activity was calculated as the difference in cytokine secretion between the treated groups in the PMA and A23187 untreated groups.
  • Equation (1) [(sample cytokine secretion-untreated cytokine secretion) / (control cytokine secretion-untreated cytokine secretion)] ⁇ 100
  • Equation (2) [1- (Sample treated cytokine secretion-untreated cytokine secretion / control cytokine secretion-untreated cytokine secretion)] ⁇ 100
  • Human keratinocyte HaCaT cells were 37 ° C. in DMEM medium supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS), 100 units / ml penicillin, and 100 ⁇ g / ml streptomycin. Incubated in a 5% CO 2 environment.
  • FBS heat-inactivated Fetal Bovine Serum
  • a Cell Counting Kit-8 (CCK-8) assay was performed. Samples were treated in HaCaT cells in 96-well plates by concentration (50, 100, 200 ⁇ g / ml) and incubated for 24 hours. After adding CCK-8 at a concentration of 10% and reacting at 37 ° C. for 2 hours, absorbance was measured at 450 nm using a microplate spectrophotometer (Biorad, Hercules, CA, USA), and compared with a control group. Relative cell viability was calculated.
  • Cultured human keratinocytes were inoculated into 6-well plates and then treated with 10ng / ml TNF- ⁇ and 10ng / ml IFN- ⁇ to induce a dermatitis response, and at various concentrations (50 , 100 and 200 ⁇ g / ml) were treated with co-culture of Nahan and the residue extract.
  • dexamethasone (Dex) Cyclosporin A was treated at concentrations of 0.01, 0.1, and 1 ⁇ M and 6, 12, and 25 ⁇ M of silymarin (silymarin), respectively.
  • the amount of chemokine secreted in the medium was measured by an ELISA kit (R & D systems Inc., Minneapolis, MN, USA). 100% activity was calculated as the difference in cytokine secretion between the treated groups in the TNF- ⁇ and IFN- ⁇ -treated groups.
  • Equation (3) [(Chemokine Secretion from Untreated Group-Chemokine Secretion from Untreated Group) / (Chemokine Secretion from Control Group-Chemokine Secretion from Untreated Group)] ⁇ 100
  • Equation (4) [1- (chemokine secretion in the treated group-chemokine secretion in the untreated group / chemokine secretion in the control group-chemokine secretion in the untreated group)] ⁇ 100.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Birds (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition, contenant un extrait de résidus de Siraitia grosvenorii à titre de principe actif, pour prévenir, soulager ou traiter l'inflammation. L'extrait de résidus de Siraitia grosvenorii à titre de principe actif selon la présente invention présente une activité anti-inflammatoire supérieure à un extrait de Siraitia grosvenorii sous forme de partie soluble, et en particulier, a un excellent effet sur la dermatite atopique, et par conséquent, la présente invention peut être avantageusement utilisée dans l'industrie des médicaments, des aliments fonctionnels pour la santé, ou des produits cosmétiques destinés à prévenir, à soulager, ou à traiter la dermatite, y compris la dermatite atopique.
PCT/KR2018/004042 2017-04-05 2018-04-05 Composition contenant un extrait de résidus de siraitia grosvenorii à titre de principe actif, pour prévenir, soulager ou traiter l'inflammation Ceased WO2018186705A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0044281 2017-04-05
KR20170044281 2017-04-05

Publications (1)

Publication Number Publication Date
WO2018186705A1 true WO2018186705A1 (fr) 2018-10-11

Family

ID=63713222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/004042 Ceased WO2018186705A1 (fr) 2017-04-05 2018-04-05 Composition contenant un extrait de résidus de siraitia grosvenorii à titre de principe actif, pour prévenir, soulager ou traiter l'inflammation

Country Status (2)

Country Link
KR (1) KR102085575B1 (fr)
WO (1) WO2018186705A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115227624A (zh) * 2022-08-30 2022-10-25 北京臻味坊食品有限公司 含坚果油的婴儿护肤油

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250055305A (ko) 2023-10-17 2025-04-24 에스아이바이오 주식회사 율무미강 잔사 발효추출물의 분획물을 포함하는 피부재생 및/또는 창상 치료용 조성물 및 이의 용도
KR20250089164A (ko) 2023-12-11 2025-06-18 국립부경대학교 산학협력단 율무미강 잔사 발효추출물을 포함하는 혈당 강하용 조성물 및 이의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106733A (ja) * 2005-10-12 2007-04-26 Saraya Kk 羅漢果抽出物およびソホロリピッドを含有する皮膚外用組成物
KR20130131508A (ko) * 2012-05-24 2013-12-04 한림대학교 산학협력단 소목(Ｃａｅｓａｌｐｉｎｉａ ｓａｐｐａｎ Ｌ.) 물 추출물 잔사의 유효성분인 ｂｒａｚｉｌｅｉｎ의 여드름 예방 및 치료용 조성물
KR20150051367A (ko) * 2013-11-04 2015-05-13 (주)화평디엔에프 나한과(Siraitia grosvenorii), 오미자(Schisandra chinensis) 및 길경(Platycodon grandiflorum) 추출물을 유효성분으로 함유하는 천식과 아토피의 예방 및 치료용 약학적 조성물
KR20150051369A (ko) * 2013-11-04 2015-05-13 (주)화평디엔에프 나한과(Siraitia grosvenorii)를 유효성분으로 함유하는 천식 및 아토피의 예방 및 치료용 약학적 조성물
KR20150132654A (ko) * 2014-05-15 2015-11-26 한국생명공학연구원 나한과 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100773856B1 (ko) * 2006-06-02 2007-11-06 주식회사 바이오랜드 나한과 추출물 또는 이로부터 분리된 트라이터펜계화합물을 함유하는 주름개선용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007106733A (ja) * 2005-10-12 2007-04-26 Saraya Kk 羅漢果抽出物およびソホロリピッドを含有する皮膚外用組成物
KR20130131508A (ko) * 2012-05-24 2013-12-04 한림대학교 산학협력단 소목(Ｃａｅｓａｌｐｉｎｉａ ｓａｐｐａｎ Ｌ.) 물 추출물 잔사의 유효성분인 ｂｒａｚｉｌｅｉｎ의 여드름 예방 및 치료용 조성물
KR20150051367A (ko) * 2013-11-04 2015-05-13 (주)화평디엔에프 나한과(Siraitia grosvenorii), 오미자(Schisandra chinensis) 및 길경(Platycodon grandiflorum) 추출물을 유효성분으로 함유하는 천식과 아토피의 예방 및 치료용 약학적 조성물
KR20150051369A (ko) * 2013-11-04 2015-05-13 (주)화평디엔에프 나한과(Siraitia grosvenorii)를 유효성분으로 함유하는 천식 및 아토피의 예방 및 치료용 약학적 조성물
KR20150132654A (ko) * 2014-05-15 2015-11-26 한국생명공학연구원 나한과 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115227624A (zh) * 2022-08-30 2022-10-25 北京臻味坊食品有限公司 含坚果油的婴儿护肤油
CN115227624B (zh) * 2022-08-30 2023-11-14 北京臻味坊食品有限公司 含坚果油的婴儿护肤油

Also Published As

Publication number Publication date
KR20180113182A (ko) 2018-10-15
KR102085575B1 (ko) 2020-03-06

Similar Documents

Publication Publication Date Title
WO2019124863A1 (fr) Composition contenant comme principe actif un extrait de feuilles de schisandra chinensis destinée à la prévention, à l'amélioration et au traitement de la dermatite atopique
WO2018186705A1 (fr) Composition contenant un extrait de résidus de siraitia grosvenorii à titre de principe actif, pour prévenir, soulager ou traiter l'inflammation
KR101793208B1 (ko) 홍자단 추출물을 포함하는 항산화 또는 항염증 조성물
KR20150022248A (ko) 삼칠근 추출물, 비누풀잎 추출물, 검정콩 잎 추출물, 녹두 잎 추출물 및 호랑이콩 잎 추출물을 포함하는 Ｔｈ2-매개 면역 질환 개선, 예방 또는 치료용 조성물
KR101964249B1 (ko) 사상자 추출물 및 카퍼트리펩타이드-1 혼합물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR101738469B1 (ko) 산사자의 에틸아세테이트 분획물 또는 n-부탄올 분획물을 포함하는 염증성 질환의 예방 또는 치료용 조성물
KR101207239B1 (ko) 천문동 추출물로부터 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물
KR101207214B1 (ko) 해방풍 추출물로부터 제조한 분획물을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물
KR101862135B1 (ko) 신규한 디노익산 화합물 및 이를 포함하는 골 질환의 예방 또는 치료용 약학적 조성물
KR102488562B1 (ko) 갯끈풀 추출물을 유효성분으로 포함하는 염증 또는 아토피 피부염의 개선, 예방 또는 치료용 조성물
KR101844890B1 (ko) 고욤나무 잎 메탄올 추출물의 에틸아세테이트 분획물을 유효성분으로 함유하는 아토피 피부염 예방 또는 개선용 조성물
KR101768280B1 (ko) 카르피너스 푸베센스 추출물을 포함하는 항산화 또는 항염증 조성물
KR102272637B1 (ko) 올벚나무를 포함하는 항염증용 조성물
KR20220059059A (ko) 지충이 추출물을 유효성분으로 포함하는 아토피 피부염 또는 알레르기성 피부염의 개선, 예방 또는 치료용 조성물
KR102757268B1 (ko) 여정실에서 유래한 신규 화합물 및 이를 포함한 염증질환 개선, 치료 또는 예방용 약학적 조성물
KR20160080513A (ko) 줄풀 추출물을 이용한 항염증용 조성물
KR102778316B1 (ko) 참비녀골풀 추출물을 유효성분으로 함유하는 아토피 피부염의 예방, 개선 또는 치료용 조성물
KR101430350B1 (ko) 데카이스니아 인시그니스 추출물을 포함하는 항산화 또는 항염증 조성물
KR20250105902A (ko) 댕강나무 추출물 또는 그 분획물을 포함하는 항염증용 조성물
KR20250105901A (ko) 댕강나무 추출물 또는 그 분획물을 포함하는 항염증용 조성물
KR101430354B1 (ko) 싸이코트리아 루브라 추출물을 포함하는 항산화 또는 항염증 조성물
KR101430352B1 (ko) 오피오리자 칸토넨시스 추출물을 포함하는 항산화 또는 항염증 조성물
KR101430351B1 (ko) 말러스 후페헨시스 추출물을 포함하는 항산화 또는 항염증 조성물
KR20250154615A (ko) 항염증용 조성물 및 이의 이용
KR20250088151A (ko) 로스팅된 오죽 잎 추출물을 유효성분으로 포함하는 아토피 피부염의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18781260

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18781260

Country of ref document: EP

Kind code of ref document: A1